Trading Update

RNS Number : 6189U

Proteome Sciences PLC

04 December 2013

 



Proteome Sciences plc

("Proteome Sciences" or the "Company")

Trading Update

In light of the recent weakness in the share price, the Directors would like to update shareholders on the Company's trading activities. We have made good progress with the SysQuant^® platform and in developing new targeted assays over the last six months and successfully completed a number of pilot studies.  Revenue for 2013 is expected to show a significant increase over 2012, driven by increased demand for PS Biomarker Services™, SysQuant^® pilot studies, TMT^® and the contract announced with Thermo Fisher Scientific.

Sales lead times however have taken longer than anticipated and the timing and revenue from a number of other contracts expected in the fourth quarter has been delayed and is now projected to fall into 2014.  Our pipeline and the level of interest continue to grow as customers shift to large-scale projects following the successful pilot studies already completed.

Our core activities are performing well and we remain confident about our prospects.

- Ends -

For further information please contact:

Proteome Sciences plc
Christopher Pearce, Chief Executive Officer	Tel: [phone]
Dr. Ian Pike, Chief Operating Officer James Malthouse, Finance Director
Nominated Adviser
Cenkos
Stephen Keys/Camilla Hume	Tel: [phone]
Public Relations
IKON Associates
Adrian Shaw
Tel: [phone]

Notes to Editors:

About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag^® (TMT^®) workflows developed on the latest Orbitrap^® Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT^® workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and diagnostics companies.

Visit:  http://www.proteomics.com

 

END

 

 

TSTUOUBRONAURAA